Clayton Lau, MD, advises primary care physicians and specialists on how to help address the rising prevalence of advanced-stage genitourinary cancers.
Clayton Lau, MD, chief, Division of Urology and Urologic Oncology, director, Prostate Cancer Program, head, Retroperitoneal Surgery, an associate clinical professor, Department of Surgery at the City of Hope Comprehensive Cancer Center, advises primary care physicians and specialists on how to help address the rising prevalence of advanced-stage genitourinary (GU) cancers.
According to a recent interview with Lau, there has been a large number of patients with advanced disease during the COVID-19 pandemic. Much of the problem is related to lack of screening, late screening, and patients not going to the doctor.
Lau believes that providers can be a part of the solution moving forward.
0:08| I think it's important for physicians, you know, specifically primary care doctors or even specialists to tell their patients to or educate the patients to continue the screening. You know, for the GU cancers, certainly for patients that have first view relatives that have prostate cancer, they probably should be screened sooner than traditionally. So, start screening patients at age 40.
0:33| Also, [for] African Americans, certainly consider screening earlier having that conversation. You know, consider screening at 40 or 45, with the PSA, rectal exam and maybe even an MRI to help determine if they have something that's, you know, they need to be biopsied. But it's important for all physicians to that, you know, to have their patients screened for all the GU cancers and other cancers.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More